Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation

British Journal of Dermatology

Volumn 175, Issue 5, 2016, Pages 882-891

  Marzano, A V ^a   Borghi, A ^b   Meroni, P L ^a   Cugno, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PROLINE SERINE THREONINE PHOSPHATASE INTERACTING PROTEIN 1; PROTEIN SERINE THREONINE KINASE; PYRIN; UNCLASSIFIED DRUG; CYTOKINE; CYTOSKELETON PROTEIN; PSTPIP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AUTOINFLAMMATORY DISEASE; BINDING AFFINITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; PAPA SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PYODERMA GANGRENOSUM; PYODERMA GANGRENOSUM ACNE SUPPURATIVE HIDRADENITIS SYNDROME; REVIEW; SAPHO SYNDROME; ACQUIRED HYPEROSTOSIS SYNDROME; AUTOIMMUNE DISEASES; BIOSYNTHESIS; DERMATITIS; GENETICS; HIDRADENITIS SUPPURATIVA; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MUTATION; SYNDROME;

ACQUIRED HYPEROSTOSIS SYNDROME; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AUTOIMMUNE DISEASES; CYTOKINES; CYTOSKELETAL PROTEINS; DERMATITIS; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; MUTATION; PYODERMA GANGRENOSUM; SYNDROME;

EID: 84983274011     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14691     Document Type: Review

References (105)

1. Callen JP. Pyoderma gangrenosum. Lancet 1996; 351:581–85.
2. Smith EJ, Allantaz F, Bennett L et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics 2010; 11:519–27.
3. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140:784–90.
4. Kundu BK, Naik AK, Bhargava S, Srivastava D. Diagnosing the SAPHO syndrome: a report of three cases and review of literature. Clin Rheumatol 2013; 32:1237–43.
5. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66:409–15.
6. Marzano AV, Ishak RS, Colombo A et al. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology 2012; 225:215–19.
7. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13:191–211.
8. Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol 2006; 55:1066–71.
9. DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015; 172:1487–97.
10. Marzano AV, Ceccherini I, Gattorno M et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 2014; 93:e187.
11. Marzano AV, Trevisan V, Gattorno M et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149:762–64.
12. Marzano AV, Fanoni D, Antiga E et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 2014; 178:48–56.
13. Doria A, Zen M, Bettio S et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012; 12:22–30.
14. Zen M, Gatto M, Domeneghetti M et al. Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity – a comprehensive review. Clin Rev Allergy Immunol 2013; 45:227–35.
15. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011; 41:1203–17.
16. Feldmeyer L, Keller M, Niklaus G et al. The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Curr Biol 2007; 17:1140–45.
17. Lee P, Lee DJ, Chan C et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 2009; 458:519–23.
18. Yiu HH, Graham AL, Stengel RF. Dynamics of a cytokine storm. PLoS ONE 2012; 7:e45027.
19. Marzano AV, Tourlaki A, Alessi E, Caputo R. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol 2008; 33:156–59.
20. Marzano AV, Cugno M, Trevisan V et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010; 162:100–7.
21. Pene J, Chevalier S, Preisser L et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008; 180:7423–30.
22. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31:252–56.
23. Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun 2015; 60:1–11.
24. Donetti E, Cornaghi L, Gualerzi A et al. An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-□ and interleukin-17. Cytokine 2014; 68:1–8.
25. Caproni M, Antiga E, Volpi W et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol 2015; 173:275–78.
26. Quaglino P, Fava P, Caproni M et al. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol 2016; 30:655–58.
27. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008; 35:515–19.
28. Marco M, Fortin C, Fulop T. Membrane-type matrix metalloproteinases: key mediators of leukocyte function. J Leukoc Biol 2013; 94:237–46.
29. Bochner BS, Zimmermann N. Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation. J Allergy Clin Immunol 2015; 135:598–608.
30. Viard-Leveugle I, Gaide O, Jankovic D et al. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013; 133:489–98.
31. Chatzigeorgiou A, Lyberi M, Chatzilymperis G et al. CD40/CD40L signaling and its implication in health and disease. BioFactors 2009; 35:474–83.
32. Lindor NM, Arsenault TM, Solomon H et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum and acne: PAPA syndrome. Mayo Clin Proc 1997; 72:611–15.
33. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin 2013; 31:405–25.
34. Tallon B, Corkill M. Peculiarities of PAPA syndrome. Rheumatology 2006; 45:1140–43.
35. Lindwall E, Singla S, Davis WE, Quinet RJ. Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome. Semin Arthritis Rheum 2015; 45:91–93.
36. Cortis E, De Benedetti F, Insalaco A et al. Abnormal production of the tumour necrosis factor alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome. J Pediatr 2004; 145:851–55.
37. Demidowich AP, Freeman AF, Kuhns DB et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012; 64:2022–27.
38. Shoham NG, Centola M, Mansfield E et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100:13501–6.
39. Yeon HB, Lindor HM, Seidman JG, Seidman CE. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 2000; 66:1443–48.
40. Wang D, Höing S, Patterson HC et al. Inflammation in mice ectopically expressing human pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome-associated PSTPIP1 A230T mutant proteins. J Biol Chem 2013; 288:4594–601.
41. Dovas A, Gevrey J-C, Grossi A et al. Regulation of podosome dynamics by WASp phosphorylation: implication in matrix degradation and chemotaxis in macrophages. J Cell Sci 2009; 122:3873–82.
42. Monypenny J, Chou H-C, Baňon-Rodriguez I et al. Role of WASP in cell polarity and podosome dynamics of myeloid cells. Eur J Cell Biol 2011; 90:198–204.
43. Cortesio CL, Wernimont SA, Kastner DL et al. Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome. Arthritis Rheum 2010; 62:2556–58.
44. Gawden-Bone C, Zhou Z, King E et al. Dendritic cell podosomes are protrusive and invade the extracellular matrix using metalloproteinase MMP-14. J Cell Sci 2010; 123:1427–37.
45. Starnes TW, Bennin DA, Bing X et al. The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages. Blood 2014; 123:2703–14.
46. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005; 22:262–65.
47. Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol 2010; 16:244–45.
48. Lee H, Park SH, Kim SK et al. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin Exp Rheumatol 2012; 30:452.
49. Brenner M, Ruzicka T, Plewig G et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161:1199–201.
50. Dinarello CA, Simon A, Van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11:633–52.
51. Kahn MF, Khan MA. The SAPHO syndrome. Bailliere Clin Rheumatol 1994; 8:333–62.
52. Nguyen MT, Borchers A, Selmi C et al. The SAPHO syndrome. Semin Arthritis Rheum 2012; 42:254–65.
53. Carneiro S, Sampaio-Barros PD. SAPHO syndrome. Rheum Dis Clin North Am 2013; 39:401–18.
54. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum 2009; 61:813–21.
55. Richette P, Molto A, Viguier M et al. Hidradenitis suppurativa associated with spondyloarthritis – results from a multicenter national prospective study. J Rheumatol 2014; 41:490–94.
56. Claudepierre P, Clerc D, Cariou D et al. SAPHO syndrome and pyoderma gangrenosum: is it fortuitous? J Rheumatol 1996; 23:400–2.
57. Naves JE, Cabré E, Mañosa M et al. A systematic review of SAPHO syndrome and inflammatory bowel disease association. Dig Dis Sci 2013; 58:2138–47.
58. Rukavina I. SAPHO syndrome: a review. J Child Orthop 2015; 9:19–27.
59. Assmann G, Simon P. The SAPHO syndrome – are microbes involved? Best Pract Res Clin Rheumatol 2011; 25:423–34.
60. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 2008; 47:1160–67.
61. Lopalco G, Cantarini L, Vitale A et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm 2015; 2015:194864.
62. Killeen ME, Ferris L, Kupetsky EA et al. Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol 2013; 190:4324–36.
63. Firinu D, Barca MP, Lorrai MM et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity 2014; 47:389–94.
64. Golla A, Jansson A, Ramser J et al. Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3–18q22. Eur J Hum Genet 2002; 10:217–21.
65. Hurtado-Nedelec M, Chollet-Martin S, Chapeton D et al. Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes. J Rheumatol 2010; 37:401–9.
66. Assmann G, Kueck O, Kirchhoff T et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther 2009; 11:R140.
67. Govoni M, Colina M, Massara A, Trotta F. SAPHO syndrome and infections. Autoimmun Rev 2009; 8:256–59.
68. Jung J, Molinger M, Kohn D et al. Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome. Semin Arthritis Rheum 2012; 42:266–70.
69. Hayama K, Inadomi T, Fujisawa D, Terui T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol 2010; 20:758–62.
70. Amital H, Applbaum YH, Aamar S et al. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 2004; 43:658–61.
71. Firinu D, Murgia G, Lorrai MM et al. Biological treatments for SAPHO syndrome: an update. Inflamm Allergy Drug Targets 2014; 13:199–205.
72. Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol 2012; 7:271–75.
73. Marzano AV, Ishak RS, Saibeni S et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 2013; 45:202–10.
74. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 2013; 147:155–74.
75. Wollina U, Haroske G. Pyoderma gangrenosum. Curr Opin Rheumatol 2011; 23:50–56.
76. Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurativa (acne inversa) as a systemic disease. Clin Dermatol 2014; 32:397–408.
77. Kistowska M, Gehrke S, Jankovic D et al. IL-1β drives inflammatory responses to Propionibacterium acnes in vitro and in vivo. J Invest Dermatol 2014; 134:677–85.
78. Qin M, Pirouz A, Kim MH et al. Propionibacterium acnes induces IL-1β secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol 2014; 134:381–88.
79. Li ZJ, Choi DK, Sohn KC et al. Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J Invest Dermatol 2014; 134:2747–56.
80. Nesterovitch AB, Hoffman MD, Simon M et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol 2011; 36:889–95.
81. Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol 2013; 22:172–77.
82. Miskinyte S, Nassif A, Merabtene F et al. Nicastrin mutations in French families with hidradenitis suppurativa. J Invest Dermatol 2012; 132:1728–30.
83. Pink AE, Simpson MA, Desai N et al. γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 2012; 133:601–7.
84. Duchatelet S, Miskinyte S, Join-Lambert O et al. First nicastrin mutation in PASH syndrome. Br J Dermatol 2015; 173:610–12.
85. Dreno B, Khammari A, Brocard A et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148:182–86.
86. Hofmann SC, Saborowski V, Lange S et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol 2012; 66:966–74.
87. André MF, Aumaître O, Grateau G et al. Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with Crohn disease in French patients. Dig Dis Sci 2010; 55:1681–88.
88. André MF, Piette JC, Kémény JL et al. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) 2007; 86:145–61.
89. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661–65.
90. Staub J, Pfannschmidt N, Strohal R et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol 2015; 29:2243–47.
91. Scheinfeld N. Diseases associated with hidradenitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J 2013; 19:18558.
92. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25:469–84.
93. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133–44.
94. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720–32.
95. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519–50.
96. Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012; 167:382–90.
97. Saïd-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. Biomed J 2012; 35:437–49.
98. Caso F, Rigante D, Vitale A et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013; 2013:51378.
99. Nguyen TV, Cowen EW, Leslie KS. Autoinflammation: from monogenic syndromes to common skin diseases. J Am Acad Dermatol 2013; 68:834–53.
100. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014; 65:223–44.
101. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620–28.
102. Lima AL, Karl I, Giner T et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol 2016; 174:514–21.
103. Federici S, Martini A, Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front Immunol 2013; 4:351.
104. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2012; 167:391–404.
105. Marzano AV, Tavecchio S, Berti E et al. Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases. Medicine (Baltimore) 2015; 94:e1818.